Boston Scientific Sales Reach $5.138 Billion as Growth Slows to 1.5%
Key Facts
Boston Scientific reported net sales of $5.138 billion in the third quarter of 2026, up 1.5% year over year, according to a summary of its earnings release published via PR Newswire. The growth rate reflects reported, operational and organic bases of measurement, according to the summary. The results followed the company’s warning in September that a cyber incident had affected manufacturing and order shipments globally. The company said at the time that the incident was likely to have a material effect on third-quarter and full-year results, and that it did not expect to meet its previous sales and adjusted earnings guidance. Final results also showed declines in net income and earnings per share under accounting standards, while adjusted earnings per share fell by less.
Net income attributable to common shareholders was $582 million, or $0.40 per share, compared with $755 million and $0.51 per share in the same period a year earlier. On an adjusted basis, the company reported $0.73 per share, versus $0.75 a year earlier. The comparison highlights lower profitability on both reported and adjusted bases, alongside limited sales growth. In the second quarter of 2026, sales were $5.442 billion, up 7.5% on a reported basis and 7.0% on operational and organic bases from a year earlier. Sales growth therefore slowed from the second to the third quarter, while quarterly sales fell from their level in the prior period.
The company linked third-quarter pressure to operational disruption caused by the cyber incident, which it said in September had disrupted manufacturing and order shipments worldwide. It warned of a potential material effect on third-quarter and fiscal 2026 results, and said it would not meet its previous sales and adjusted earnings guidance. Chief Executive Mike Mahoney described the year as “a challenging year for Boston Scientific” and said he was proud of the response from its global teams, “particularly to the cyber incident.” He added that teams had worked to restore operations and support customers and patients, according to the earnings release. This places the sales slowdown and earnings decline in the context of operational disruption that the company said extended to manufacturing and shipping.
Boston Scientific updated its fourth-quarter outlook, forecasting that reported and organic sales would decline about 1% to 3% year over year. It also forecast adjusted earnings of between $0.77 and $0.79 per share for the quarter. For fiscal 2026, the company is targeting reported sales growth of about 4.25% and adjusted earnings of between $3.16 and $3.18 per share. The fourth-quarter outlook follows the September warning that the company would not meet its previous sales and adjusted earnings guidance, while the results released provided a new estimate for the rest of the year. A conference call to discuss third-quarter results was scheduled for October 28, 2026, at 8:00 a.m. U.S. Eastern Time.
The company’s shares, BSX, closed at $45.06 on October 27, 2026, according to EL7 data. The close came a day before the results call scheduled for October 28; available data do not include the stock’s session high and low. In the second quarter, the company reported quarterly sales of $5.442 billion and stronger year-over-year growth than in the third quarter. The comparison between the two periods provides a picture of slowing sales momentum before the fourth-quarter outlook takes effect. The quarterly and annual outlooks announced by the company will serve as its framework for tracking performance through the remainder of 2026.